Table 2.

The role of m⁶A-binding proteins in human solid cancers and hematological malignancy

Cancers	m6A readers	Target RNAs	Mechanism	Reference
Hepatocellular carcinoma	YTHDF1	Snail	Accelerating the translation of Snail mRNA	[47]
	YTHDF2	EGFR	Destabilizing EGFR mRNA	[42]
	YTHDF2	IL-11, SERPINE2	Increasing the degradation of IL-11 and SERPINE2 mRNAs	[43]
	YTHDF2	SOCS2	Facilitating SOCS2 mRNA decay	[44]
	IGF2BP1/2/3	MYC	Enhancing the expression of MYC mRNA	[32]
	IGF2BP1	SRF	Promoting SRF mRNA translation	[48]
Colorectal cancer	YTHDF1	β-catenin, WNT6, FZD9	Increasing the expression of β-catenin, WNT6 and FZD9A to activate Wnt/β-catenin pathway	[49]
	YTHDF3	GAS5	Enhancing the degradation of lncRNA GAS5	[50]
	YTHDC1	circNSUN2	Facilitating circNSUN2 export from nucleus to cytoplasm	[51]
	IGF2BP2	HMGA2	Forming a circNSUN2/IGF2BP2 complex to fortify the stability of HMGA2	[51]
	IGF2BP2	SOX2	Stabilizing SOX2 mRNA	[52]
Gastric cancer	IGF2BP1	SEC62	Augmenting SEC62 mRNA translation	[53]
	IGF2BP3	HDGF	Facilitating HDGF mRNA expression	[54]
	HuR	ZMYM1	Fortifying the stability of ZMYM1 mRNA	[116]
Lung cancer	YTHDF1	CDK2, CDK4, cyclinD1	Promoting the translations of CDK2, CDK4 and cyclinD1	[56]
	YTHDF1	Keap1	Leading to cisplatin resistance of tumor cells via modulating the Keap1-Nrf2-AKR1C1 axis	[56]
	YTHDF1/3	YAP	Up-regulating YAP expression	[57]
	YTHDF2	6PGD	Facilitating 6PGD degradation	[55]
	YTHDF3	MALAT1	Increasing MALAT1 stability	[57]
	MELLT3	EGFR, TAZ	Accelerating the translation of EGFR and TAZ	[58]
Bladder cancer	YTHDF1/3	ITGA6	Promoting ITGA6 mRNA translation	[59]
	YTHDF1	CDCP1	Enhancing the expression of CDCP1 mRNA	[60]
	MELLT3	CDCP1	Facilitating CDCP1 translation and strengthening the binding of YTHDF1 to CDCP1	[60]
Endometrial cancer	YTHDF1	PHLPP2	Increasing the expression of PHLPP2	[61]
	YTHDF2	PRR5, PRR5L, mTOR	Diminishing the abundance of PRR5, PRR5L, and mTOR	[61]
Ovarian cancer	YTHDF1	EIF3C	Targeting at EIF3C to enhance its translation efficiency	[62]
Cervical cancer	YTHDF2	GAS5	Abrogating the GAS5 expression	[63]
Melanoma	YTHDF2	PD-1 (PDCD1), CXCR4, SOX10	Downregulating the mRNA and protein levels of three key intrinsic pro-tumorigenic factors, including PD-1 (PDCD1), CXCR4 and SOX10	[64]
	YTHDF1	HINT2	Promoting the translation of HINT2 mRNA	[65]
Breast cancer	YTHDF2	BNIP3	Facilitating the degradation of BNIP3 mRNA	[66]
Pancreatic cancer	IGF2BP2	DANCR	Enhancing the DANCR expression	[67]
Acute myeloid leukemia	YTHDF2	TNFR2	Reducing the TNFR2 expression	[81]
	YTHDF2	MYC, CEBPA	Accelerating the decay of MYC and CEBPA	[82]